ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / MTNB
SPRC (47) OGEN (40) KAPA (37) BDRX (47) ⌘ Pro Terminal →

Matinas Biopharma Holdings Inc. (MTNB) — RQD Stock Rating Cockpit

$1.29 -14.57% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.25

Matinas Biopharma Holdings Inc. (MTNB) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $1.5M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MTNB Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MTNB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Matinas Biopharma Holdings Inc. (NYSE: MTNB) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $1.29 (-14.57% 1D, market cap $1.5M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, MTNB ranks #617 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MTNB compare to SPRC and OGEN in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MTNB carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SPRC (SciSparc Ltd.) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $1.4M) and OGEN (Oragenics Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $1.7M). Among the 5-stock peer group, MTNB leads on earnings multiple (N/A) while MTNB leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MTNB?
▼

Per MTNB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001582554), Matinas Biopharma Holdings Inc. generated $19.5M in revenue (-71.7% YoY), -$10.3M in net income, and -$7.0M in free cash flow against $7.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.25 (-2.81%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510035
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (7)Whales (3)SEC (10)Macro (10)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-10.1% Base Target
$14 Bull$1 Base$1 Bear
📬 FREE MTNB RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MTNB)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (35/100 Composite)
🔍 WHY MTNB SCORES 35/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (29% of score)

FRED Regime × Technicals: 6% of 52W Range • RSI-14 at 37.3 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
43
Grade D$2.50-32% Next Q
Q2 (-2Q)
40
Grade D$1.70+7.6% Next Q
Q3 (-1Q)
38
Grade E$1.83-29.5% Next Q
Current
35
Grade D-$1.29-8.5% Hist 90D α
Trajectory: D (43) → D- (35)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a MTNB Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While MTNB currently carries a cautious 35/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.47) and Max Pain ($1.35) forces dealer call-delta covering toward $14.28.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MTNB• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MTNB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 35%NO 65%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
37.330 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
3 / 99-Pt Accounting
52-WEEK LASER RANGE6% OF RANGE
L: $1$1.29H: $14
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 8 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 20 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on MTNB

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (35)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (30)

8/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like MTNB
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MTNB)

  • ✓Walkthrough of MTNB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
MTNB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -87.16%⚡ TESTING RESISTANCE
2026-11-03O $1.90H $1.90L $1.29C $1.29VOL 83.0K
RES: $1.71SUP: $1.16SMA50: $2.47SMA200: $6.91
$14.46$10.89$7.32$3.75$0.18RES $1.71SUP $1.16$1.292026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MTNB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MTNB Butterfly Map → + Track MTNB →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on MTNB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MTNB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MTNB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MTNB)

Health Care Rank #617 of 1016 ⚔️ SPRC vs MTNB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MTNB vs. SPRC, OGEN, KAPA, BDRX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Matinas Biopharma Holdings Inc. (MTNB) ranks #617 by composite RQD confidence (35/100, grade D-) and #1007 by equity capitalization ($1.5M). Within this direct 5-issuer industry benchmark cohort, MTNB leads on earnings valuation at N/A trailing P/E, while MTNB leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. SPRC currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with MTNB at 35/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
MTNB ACTIVE
Matinas Biopharma Holdings Inc.
D- 35/100 — — -35.0% -14.57% $1.5M Benchmark Subject
SPRC
SciSparc Ltd.
D 47/100 — — — -11.64% $1.4M /sprc-vs-mtnb →
OGEN
Oragenics Inc.
D- 40/100 — — -35.0% -1.02% $1.7M /ogen-vs-mtnb →
KAPA
Kairos Pharma Ltd.
D- 37/100 — — -35.0% -10.66% $1.8M /kapa-vs-mtnb →
BDRX
Biodexa Pharmaceuticals plc American Depositary Shs
D 47/100 — — — -18.37% $1.8M /bdrx-vs-mtnb →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001582554

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Matinas Biopharma Holdings Inc. (MTNB) reported GAAP revenue of $19.5M (-71.7% vs. FY2024 revenue of $68.9M , and +1678.1% cumulative change since FY2023) , GAAP net income of -$10.3M, operating cash flow of -$7.0M, and free cash flow of -$7.0M (+55.9% YoY). On the balance sheet, MTNB closed FY2025 with $7.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $19.5M -$10.3M -$7.0M -$7.0M $7.2M —
FY2024 (FY) 2024-12-31 $68.9M -$24.3M -$15.9M -$15.9M $12.6M —
FY2023 (FY) 2023-12-31 $1.1M -$22.9M -$15.3M -$15.3M — —

3. MTNB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MTNB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Matinas Biopharma Holdings Inc. (NYSE: MTNB) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $1.29 (-14.57% 1D, market cap $1.5M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, MTNB ranks #617 in composite RQD confidence.

How does MTNB compare to SPRC and OGEN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MTNB carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SPRC (SciSparc Ltd.) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $1.4M) and OGEN (Oragenics Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $1.7M). Among the 5-stock peer group, MTNB leads on earnings multiple (N/A) while MTNB leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MTNB?

Per MTNB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001582554), Matinas Biopharma Holdings Inc. generated $19.5M in revenue (-71.7% YoY), -$10.3M in net income, and -$7.0M in free cash flow against $7.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MTNB trading relative to its 50-day, 200-day, and 52-week technical levels?

MTNB last traded at $1.29 (-14.57% on volume of 224,174 shares), positioning the stock -47.77% below its 50-day simple moving average ($2.47) and -81.33% below its 200-day simple moving average ($6.91). Across its 52-week range of $0.56 to $13.60, MTNB sits at the 5.6% percentile with a 14-day RSI of 37.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.13 to $1.45).

Direct Sub-Reports: MTNB RQD Cockpit MTNB 12M Forecast MTNB Earnings & Move MTNB Dividends & DRIP MTNB Insiders & 13F MTNB Whale Options MTNB Profit Sankey MTNB News & Why
ROARABLE RATING BRIEF • RQD 35/100 (D-) ✓ SEC XBRL & RQD VERIFIED

MTNB — Matinas Biopharma Holdings Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Matinas Biopharma Holdings Inc. (MTNB) earns a live Roarable RQD composite score of 35/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $1.29 (-14.57% 1D, market capitalization $1.5M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (10/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Matinas Biopharma Holdings Inc. Is a NYSE-listed company in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry (per the company profile). Reported revenue is — for FY 2025 and FY 2024 and $1.1M for FY 2023 ().

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Matinas Biopharma Holdings Inc. (MTNB) reported $19.5M in annual revenue (up from $68.9M in FY2024, -71.7% YoY) and -$10.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.1M revenue, -$22.9M net income) through FY2025, MTNB scaled operating cash flow to -$7.0M and free cash flow to -$7.0M, backed by $7.2M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 35/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.56 – $13.60 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and bottlenecks cannot be identified from the source data.

  • Key Question #1: Can MTNB sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $19.5M and free cash flow of -$7.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is MTNB's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

MTNB Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Matinas Biopharma Holdings Inc. (MTNB) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MTNB Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MTNB Bull vs. Bear Conversation Board — What's Your Call at $1.29?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MTNB 🐻 33% BEARISH CONVICTION
1. Pick Your Side on MTNB:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $1.92 (+27.2%)
📌 Pinned Debate

The stock trades at $1.9 against a 52-week range of $0.56 to $13.6, with a beta of 1.0 and a reported Altman Z of 2.5 that sits above d

The stock trades at $1.9 against a 52-week range of $0.56 to $13.6, with a beta of 1.0 and a reported Altman Z of 2.5 that sits above distress territory.. When you look under the hood at MTNB, Fundamental Cash Engine is 7/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $13.60. My 12M target is $1.92.

SectorRotator 🐂 BULL

@FadeTheHype Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $1.24 (-17.9%)
Spot @ $1.51

The RQD rating of 35 (D-) reflects a -35% ROIC, a 0% FCF yield, a Whale/13F Flow pillar score of 3/20, and zero revenue in FY 2024 and

Fading this rally in MTNB at $1.51. The RQD rating of 35 (D-) reflects a -35% ROIC, a 0% FCF yield, a Whale/13F Flow pillar score of 3/20, and zero revenue in FY 2024 and FY 2025.. With a beta of 1.0 and the stock sitting at $1.51 (52-wk range $0.56–$13.60), the easy multiple expansion is already priced in.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%